FOLH1 and prostate adenocarcinoma: The first was published in 2015 by Chakraborty et al., in which they reported a prostatic adenocarcinoma patient without neurologic symptoms, who demonstrated avid 68Ga-PSMA-11 (HBED-CC) uptake in three separate MRI-diagnosed brain metastases, in the cerebellar hemisphere and bifrontal lobes [57].